Several MDM2 inhibitors have been developed, including small molecules like Nutlin-3, RG7112, and MI-219. These compounds bind to the p53-binding pocket of MDM2, preventing the ubiquitination and degradation of p53. Such inhibitors are currently being tested in clinical trials for their efficacy in treating various cancers.
